Polaryx Therapeutics' Drug in the FDA Approval Process
This section highlights FDA-related milestones and regulatory updates for drugs developed by Polaryx Therapeutics (PLYX).
Over the past two years, Polaryx Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
PLX-200. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
PLX-200 FDA Regulatory Events
PLX-200 is a drug developed by Polaryx Therapeutics for the following indication: For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- PLX-200
- Announced Date:
- April 21, 2026
- Indication:
- For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis
Announcement
Polaryx Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II).
AI Summary
Polaryx Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II). These are rare, serious genetic disorders that cause progressive neurodegeneration in children. PLX-200 is being developed to address the underlying disease processes, and these FTD decisions apply to its study in the company’s planned SOTERIA Phase 2 basket trial covering these indications.
The Fast Track program is intended to speed development and review of drugs for serious conditions with unmet medical need. Companies with FTD often get more frequent contact with the FDA and may be eligible for rolling review of a future marketing application. Those features can help shorten development timelines and potentially bring treatments to patients sooner.Read Announcement
- Drug:
- PLX-200
- Announced Date:
- March 17, 2026
- Indication:
- For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis
Announcement
Polaryx Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease).
AI Summary
Polaryx Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease). Fast Track is meant to help speed the development and review of drugs for serious conditions with unmet medical needs. The designation can allow more frequent communication with the FDA and may enable a rolling review of a future marketing application, which could shorten the time to reach patients if trials are successful.
This regulatory milestone supports Polaryx’s SOTERIA Phase 2 basket trial, an open-label, single-arm study testing PLX-200’s safety, tolerability, and clinical activity across four rare lysosomal storage disorders: CLN2, CLN3, Krabbe disease, and Sandhoff disease. The Fast Track status may help advance the program as the company continues clinical development.
Read Announcement
Polaryx Therapeutics FDA Events - Frequently Asked Questions
As of now, Polaryx Therapeutics (PLYX) has not received any FDA approvals for its therapy in the last two years.
In the past two years, Polaryx Therapeutics (PLYX) has reported FDA regulatory activity for PLX-200.
The most recent FDA-related event for Polaryx Therapeutics occurred on April 21, 2026, involving PLX-200. The update was categorized as "Designation Grant," with the company reporting: "Polaryx Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II)."
Currently, Polaryx Therapeutics has one therapy (PLX-200) targeting the following condition: For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis.
More FDA Event Resources from MarketBeat
Companies With Recent FDA Events
FDA Event Stage Terminology & Abbreviation Guide
- NDA: New Drug Application
- ANDA: Abbreviated New Drug Application
- sNDA: Supplemental New Drug Application
- BLA: Biologics License Application
- sBLA: Supplemental Biologics License Application
- FDA Approved: Approved by the FDA
- EMA: European Medicines Agency
- CE Mark: European Union Certification
- NMPA: China National Medical Products Administration
- MHLW: Japanese Ministry of Health
- FDA Meeting: Consultation with FDA
- Pre-IND: Pre-Investigational New Drug Meeting
- Breakthrough Therapy: Special FDA designation for promising therapies
- Fast Track: Accelerated FDA approval pathway
- Orphan Drug: Designation for rare disease treatments
- RPD: Rare Pediatric Disease Designation
- RMAT: Regenerative Medicine Advanced Therapy
- DSMB Review: Data Safety Monitoring Board Review
- IDMC Review: Independent Data Monitoring Committee
- MAA: MHRA Marketing Authorization Application
- RTF: Refusal to File (Rejected Application)
- 510(k): FDA Clearance for Medical Devices
- Rolling Submission: Staggered regulatory review process
FDA progress for NASDAQ:PLYX last updated on 4/21/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
